A Double-Blind Trial of the Effect of Beta-Sitosteryl Glucoside (WA184) in the Treatment of Benign Prostatic Hyperplasia

Publisher Website
Google Scholar
Abstract
Cholesterol-lowering agents are still used in some countries for the treatment of benign prostatic hyperplasia(BPH). A randomized, double-blind, placebo-controlled urodynamic study, carried out on 53 patients with proven outflow obstruction, has failed to prove that the drug, ß-sitosteryl ß-Z)-glucoside (WA 184), is superior to placebo in the treatment of outflow obstruction due to BPH when administered at a dose of 0.3 mg/day. Possible reasons for this include an insufficient dose and duration of treatment (this drug is known to have a potent effect on cholesterol metabolism in the prostate) and the predominantly stromal pathological changes which characterize BPH and which may be unaffected by such agents.